Overview

A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)

Status:
Not yet recruiting

Trial end date:
2023-03-28

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to is to assess the ability of retina specialists to successfully administer, via an intravitreal (IVT) injection, a 2 mg dose of ABP 938, using the ABP 938 aflibercept prefilled syringe (PFS), compared to a 2 mg dose of aflibercept using the aflibercept PFS.

Phase:

Phase 3

Details

Lead Sponsor:

Amgen

Treatments:

Aflibercept